Aberdeen Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Aberdeen Group’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-32,217	Closed	-$10.2M	–	980
2023 Q4	$10.2M	Buy	+32,217	New	+$6.26M	0.02%	544

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Aberdeen Group's KRTX Position: Q1 2024 in Review

Aberdeen Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 32,217 shares — an estimated $10.2M sold.

Aberdeen Group first reported a position in KRTX in Q4 2023 and held it in 1 quarter. The position peaked at $10.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Aberdeen Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Aberdeen Group sold 32,217 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $10.2M.
Aberdeen Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Aberdeen Group's Karuna Therapeutics, Inc. Common Stock position peaked at $10.2M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Aberdeen Group's 13F filing for Q1 2024, filed 9 May 2024.